We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Stem Cell Therapeutics Announces Issuance of Patents in India

Read time: Less than a minute
Stem Cell Therapeutics Corp. has been issued two patents in India: Indian Patent No. 229684 entitled, "Combined Regulation of Neural Cell Production" and Indian Patent No. 229924 entitled, "A Composition for Increasing Neural Stem Cell Number and In Vitro Method of Using the Same".

Together, these patents cover pharmaceutical compositions for increasing neural stem cell number or for producing specialized neural stem cell progeny, with the compositions comprising prolactin in combination with other neural stem cell proliferating agents or differentiating agents, such as erythropoietin ("EPO").

Methods for using prolactin and other such agents in neural stem cell culture are also covered, with the resulting cells being useful, for example, in regenerative transplant therapy.

Dr. Alan Moore, President and CEO, commented as follows: "Overall, India is playing a valuable role in our development programs. It is therefore increasingly important to address intellectual property issues in India. These two patents are part of that process."
Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.